AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2146996 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking index (BI)
Number of subjects: 0
Study 2146996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation index (SI)
Number of subjects: 0
Study 70341 — intervention group
Group type: EXPERIMENTAL
Intervention: Target shocks (1 mA above subjective threshold)
Number of subjects: 12
Study 70341 — intervention group
Group type: COMPARATOR
Intervention: Non-target shocks
Number of subjects: 12
Study 70341 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaker shocks
Number of subjects: 12
Study 70341 — intervention group
Group type: EXPERIMENTAL
Intervention: Task conditions
Number of subjects: 12
Study 70341 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong shocks
Number of subjects: 12
Study 70341 — intervention group
Group type: EXPERIMENTAL
Intervention: Target shocks
Number of subjects: 12
Study 31731006 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation (PN) intervention including strengths‐based case management, 1‐1 clinical support, motivational interviewing, and addiction‐relapse prevention programming.
Number of subjects: 0
Study 30014671 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Hegu (LI 4), Neiguan (PC 6) and Zusanli (ST 36) 20 min before operation; EA combined with regular anesthesia during operation
Number of subjects: 60
Study 30014671 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of parecoxib sodium (40 mg), combined with regular anesthesia
Number of subjects: 60
Study 30014671 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of dezocine (5 mg), combined with regular anesthesia
Number of subjects: 60
Study 26659833 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133+ cells
Number of subjects: 27
Study 26659833 — intervention group
Group type: EXPERIMENTAL
Intervention: MNCs
Number of subjects: 27
Study 26659833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24145207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test tolerance
Number of subjects: 12981
Study 24145207 — intervention group
Group type: COMPARATOR
Intervention: Other experimental pain modalities
Number of subjects: 12981
Study 24145207 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery as a cause of chronic pain
Number of subjects: 12981
Study 21942288 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing immediately after bleaching
Number of subjects: 80
Study 21942288 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing 1 hour after bleaching
Number of subjects: 80
Study 21942288 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing 2 hours after bleaching
Number of subjects: 80
Study 21942288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no toothbrushing)
Number of subjects: 80
Study 19070440 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg aripiprazole
Number of subjects: 0
Study 19070440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg aripiprazole
Number of subjects: 0
Study 19070440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg and 10mg aripiprazole
Number of subjects: 0
Study 19070440 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 19070440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17623736 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 0.4 g/kg per month
Number of subjects: 231
Study 17623736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 16220024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (6 sessions)
Number of subjects: 12
Study 16220024 — intervention group
Group type: COMPARATOR
Intervention: Control group (prior to antidepressive treatment)
Number of subjects: 12
Study 14578019 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.005 mg/kg)
Number of subjects: 64
Study 14578019 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 64
Study 9923795 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous insulin (n = 8)
Number of subjects: 13
Study 9923795 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 5)
Number of subjects: 13
Study 7538682 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane-covered self-expanding metallic endoprosthesis
Number of subjects: 32
Study 2103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy (daily doses of 600 micrograms organic selenium, 9000 IU beta carotene, 0.54 g vitamin C, 270 IU vitamin E, and 2 g methionine)
Number of subjects: 28
Study 2103755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy
Number of subjects: 28
Study 6990476 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 degrees 'jack-knife' position
Number of subjects: 78
Study 6990476 — intervention group
Group type: COMPARATOR
Intervention: 45 degrees 'jack-knife' position
Number of subjects: 78
Study 29490041 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused wellness intervention (seven-week duration)
Number of subjects: 0
Study 29490041 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 27080156 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic diagnostic scoring instrument
Number of subjects: 7262
Study 27080156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced diagnostic scoring instrument
Number of subjects: 7262
Study 24582799 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate pre-rinse (CaL, 150mmol/L, 1min) followed by fluoride rinse (NaF 12mmol/L, 1min)
Number of subjects: 15
Study 24582799 — intervention group
Group type: COMPARATOR
Intervention: Fluoride rinse only (NaF 12mmol/L, 1min)
Number of subjects: 15
Study 24582799 — intervention group
Group type: COMPARATOR
Intervention: No rinse (negative control)
Number of subjects: 15
Study 22257577 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 (glycopyrronium bromide) at doses of 25, 50, 100, or 200 μg
Number of subjects: 0
Study 22257577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20417567 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 1267
Study 20417567 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg
Number of subjects: 1267
Study 20417567 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1267
Study 18703600 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation for relief of angina
Number of subjects: 23
Study 15797163 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered, self-efficacy based intervention (6 sessions every 2 weeks)
Number of subjects: 65
Study 15797163 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 15797163 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered, self-efficacy based intervention
Number of subjects: 65
Study 12876902 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated split‐virion (Imovax Gripe)
Number of subjects: 344
Study 12876902 — intervention group
Group type: COMPARATOR
Intervention: Sub‐unit (Agrippal S1)
Number of subjects: 344
Study 10379328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fixation with intramedullary nailing
Number of subjects: 24
Study 10379328 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic fixation with dynamic compression plating
Number of subjects: 24
Study 10379328 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic fixation with Rush rodding
Number of subjects: 24
Study 10379328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fixation with locked intramedullary nailing
Number of subjects: 24
Study 10379328 — intervention group
Group type: COMPARATOR
Intervention: Intact humeri
Number of subjects: 24
Study 10379328 — intervention group
Group type: EXPERIMENTAL
Intervention: Humeri with a 50% hemicylindrical cortical central 1/3 defect
Number of subjects: 24
Study 8707580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (Fenistil gel)
Number of subjects: 12
Study 8707580 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiderm
Number of subjects: 12
Study 8707580 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 12
Study 8707580 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine‐Salbe 5%
Number of subjects: 12
Study 8707580 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream corresponding to Optiderm
Number of subjects: 12
Study 2050319 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU of interferon-alpha 2b/m2 body surface area three times a week (group I)
Number of subjects: 36
Study 2050319 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of interferon-alpha 2b/m2 body surface area three times a week (group II)
Number of subjects: 36
Study 2050319 — intervention group
Group type: COMPARATOR
Intervention: Control group (group III)
Number of subjects: 36
Study 2050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 36
Study 6197081 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the primary site followed by 10 pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU)
Number of subjects: 186
Study 6197081 — intervention group
Group type: COMPARATOR
Intervention: Two pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU) followed by radiotherapy and then 8 pulses of chemotherapy
Number of subjects: 186
Study 30219959 — intervention group
Group type: EXPERIMENTAL
Intervention: English text
Number of subjects: 51
Study 30219959 — intervention group
Group type: EXPERIMENTAL
Intervention: English text with pictorial illustrations
Number of subjects: 51
Study 30219959 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic novel
Number of subjects: 51
Study 30219959 — intervention group
Group type: COMPARATOR
Intervention: Within-subject comparison
Number of subjects: 51
Study 29331975 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative orthosis for 6 weeks followed by 6 weeks of weaning
Number of subjects: 46
Study 29331975 — intervention group
Group type: COMPARATOR
Intervention: No postoperative orthosis
Number of subjects: 46
Study 26986091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 48
Study 26986091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25428213 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (lifestyle intervention)
Number of subjects: 425
Study 25428213 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care (control)
Number of subjects: 425
Study 22810146 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV serostatus (measured by CMV IgG antibodies)
Number of subjects: 1230
Study 22810146 — intervention group
Group type: COMPARATOR
Intervention: Control group (men not diagnosed with PCa)
Number of subjects: 1230
Study 20216555 — intervention group
Group type: EXPERIMENTAL
Intervention: Active FM (fermented milk containing Lactobacillus gasseri SBT2055), n=43, 200 g/day for 12 weeks
Number of subjects: 87
Study 20216555 — intervention group
Group type: COMPARATOR
Intervention: Control FM (fermented milk without Lactobacillus gasseri SBT2055), n=44, 200 g/day for 12 weeks
Number of subjects: 87
Study 17505679 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TEA (15 ml 0.5% bupivacaine)
Number of subjects: 19
Study 17505679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 ml 0.9% saline)
Number of subjects: 19
Study 15322696 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI+GC
Number of subjects: 0
Study 15322696 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI+CBT
Number of subjects: 0
Study 15322696 — intervention group
Group type: COMPARATOR
Intervention: PL+GC
Number of subjects: 0
Study 15322696 — intervention group
Group type: COMPARATOR
Intervention: PL+CBT
Number of subjects: 0
Study 11914400 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PPMS
Number of subjects: 30
Study 11914400 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 9802851 — intervention group
Group type: COMPARATOR
Intervention: SCD
Number of subjects: 68
Study 9802851 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 68
Study 9802851 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD/enoxaparin
Number of subjects: 68
Study 8533119 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg/day, 200 mg/day, or 300 mg/day for 14 weeks
Number of subjects: 56
Study 8533119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2689261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 60
Study 2689261 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 60
Study 2689261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1101478 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (ATG) with azathioprine and prednisone
Number of subjects: 2
Study 1101478 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisone alone
Number of subjects: 2
Study 31283908 — intervention group
Group type: EXPERIMENTAL
Intervention: nabilone (0.5 mg)
Number of subjects: 20
Study 31283908 — intervention group
Group type: EXPERIMENTAL
Intervention: nicotine (6 mg)
Number of subjects: 20
Study 31283908 — intervention group
Group type: EXPERIMENTAL
Intervention: nicotine (6 mg) + nabilone (0.5 mg)
Number of subjects: 20
Study 31283908 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 28094198 — intervention group
Group type: EXPERIMENTAL
Intervention: APBI with interstitial brachytherapy
Number of subjects: 1184
Study 28094198 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1184
Study 26334853 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cells (RBC) transfusion during ECC
Number of subjects: 30
Study 26334853 — intervention group
Group type: COMPARATOR
Intervention: No RBC transfusion during ECC
Number of subjects: 30
Study 26334853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RBC transfusion and no transfusion)
Number of subjects: 30
Study 23004922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d) ingested 8 hours after awakening
Number of subjects: 350
Study 23004922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d) ingested at bedtime
Number of subjects: 350
Study 23004922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d) ingested upon awakening
Number of subjects: 350
Study 23004922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d)
Number of subjects: 350
Study 16856895 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser excision
Number of subjects: 50
Study 16856895 — intervention group
Group type: COMPARATOR
Intervention: Conventional gingivectomy
Number of subjects: 50
Study 16856895 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery
Number of subjects: 50
Study 12647193 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency ventilation (HFV)
Number of subjects: 300
Study 12647193 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 300
Study 10929272 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids or adrenocorticotropic hormone (ACTH) treatment
Number of subjects: 1714
Study 10929272 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids or ACTH treatment
Number of subjects: 1714
Study 8799525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 0
Study 8799525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 0
Study 8799525 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0
Study 8799525 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 0
Study 8799525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1344236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine 25mg IM
Number of subjects: 60
Study 1344236 — intervention group
Group type: COMPARATOR
Intervention: 0.9% N/S 0.5ml IM (Control)
Number of subjects: 60
Study 6424464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antibiotics and isolation in laminar airflow room (36 patients)
Number of subjects: 101
Study 6424464 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic granulocyte transfusions from a single family member donor (33 patients)
Number of subjects: 101
Study 6424464 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in single rooms with hand-washing and mask precautions (31 patients)
Number of subjects: 101
Study 6424464 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminar airflow room (36 patients)
Number of subjects: 101
Study 31730539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 90
Study 31730539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with Damask rose essential oil
Number of subjects: 90
Study 31730539 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90
Study 31445838 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataXRT®
Number of subjects: 197
Study 31445838 — intervention group
Group type: COMPARATOR
Intervention: Sorbolene (10% Glycerine)
Number of subjects: 197
Study 27995837 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 4% chlorhexidine scrub
Number of subjects: 240
Study 27995837 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterless hand rub (1% chlorhexidine gluconate and 61% ethyl alcohol)
Number of subjects: 240
Study 27995837 — intervention group
Group type: COMPARATOR
Intervention: Conventional 10% povidone‐iodine scrub
Number of subjects: 240
Study 25767380 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) performed three times per week (G3x)
Number of subjects: 53
Study 25767380 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RT) performed two times per week (G2x)
Number of subjects: 53
Study 24040974 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor probe
Number of subjects: 18
Study 24040974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant odor probe
Number of subjects: 18
Study 24040974 — intervention group
Group type: COMPARATOR
Intervention: Neutral odor
Number of subjects: 18
Study 20969725 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20
Study 20969725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20017349 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcholine nephroprotector during CAG
Number of subjects: 36
Study 20017349 — intervention group
Group type: COMPARATOR
Intervention: CAG without nephroprotection
Number of subjects: 36
Study 17347567 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 8-week training program of mobility and toileting skills
Number of subjects: 57
Study 17347567 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 57
Study 15547093 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment (5 mg/kg)
Number of subjects: 49
Study 11560099 — intervention group
Group type: EXPERIMENTAL
Intervention: EE20/GSD75
Number of subjects: 216
Study 9747153 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (20 mg administered locoregionally over 4 hours for a maximum of 7 days)
Number of subjects: 69
Study 9747153 — intervention group
Group type: EXPERIMENTAL
Intervention: urokinase (100,000 IU/h administered locoregionally for a maximum of 7 days)
Number of subjects: 69
Study 9747153 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous heparin infusions after PTT)
Number of subjects: 69
Study 7831457 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 2467608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 31
Study 2467608 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) - penicillin-chloramphenicol combination with or without sulphadiazine
Number of subjects: 31
Study 2467608 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 31
Study 31586206 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) during maintenance chemotherapy (Group 1)
Number of subjects: 118
Study 31586206 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) at end of chemotherapy (Group 2)
Number of subjects: 118
Study 31586206 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) 6 months after chemotherapy (Group 3)
Number of subjects: 118
Study 28292331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for depression, 16-20 sessions
Number of subjects: 104
Study 28292331 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy for depression, 16-20 sessions
Number of subjects: 104
Study 28292331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104
Study 28292331 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy for depression
Number of subjects: 104
Study 26430087 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 high-risk genotype
Number of subjects: 693
Study 26430087 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m(2))
Number of subjects: 693
Study 26430087 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary excretion of urea nitrogen (≥ 8 g/d)
Number of subjects: 693
Study 23428922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment
Number of subjects: 314
Study 23428922 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin treatment
Number of subjects: 314
Study 21481998 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit task with self-selected actions
Number of subjects: 0
Study 21481998 — intervention group
Group type: COMPARATOR
Intervention: Incompatible spatial training
Number of subjects: 0